Gateway focuses on transformational science via effective clinical trials—when basic science translates into human testing and clinical practice. We invest in clinical trials to enroll patients at all ages, with all cancer types, whose cancer is at any stage of progress—as long we they have the potential to help people live longer and feel better.
We accept submissions on a rolling basis and typically approve funding requests within 3-4 months—an extraordinarily short timeline compared to most research funding streams. As a result, Investigators can capitalize on Gateway funding to quickly enroll patients and move the research forward more rapidly than most funding allows.
Together with the Director of Research and Grants, Gateway's Board of Scientific Counselors evaluate proposed research and monitor funded research. Grants are approved for up to two years of funding contingent upon investigators following Gateway’s reporting protocol. The updates must demonstrate not only fiscal responsibility, but also show real progress through measurable patient impact.
The application process has a rolling Letter of Intent (LOI) submission which is aggregated four times a year.
NCI / SPORE Program
Gateway is partnering with the NCI to give SPORE recipients the opportunity to apply for supplemental funding for their early phase, innovative clinical trials. The Gateway funding could enable principal investigators and their respective institutions to start a new trial by adding an additional arm, add patient cohorts and/or new correlative analysis. Funding cannot duplicate scope of work of the SPORE award.
Grants are generally awarded for a 2-5 year period, with total award amounts generally ranging from $200,000 to $800,000.
GFCR Grant Program
These core grants fund early phase clinical trials for cancers of all types at renowned institutions around the world. Grants are typically 2-5 years in duration with award amounts from $200,000 to $1.5 million.
GFCR Integrative Program
Gateway is focused on funding integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. Grants are generally awarded for a 2-5 year period, with total award amounts generally ranging from $200,000 to $1.5 million.
SIO Integrative Program
Gateway is focused on funding integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment. Grants are generally awarded for a 2-5 year period, with total award amounts generally ranging from $200,000 to $1.5 million.
